

PHARMACY POLICY STATEMENT

Indiana Medicaid

DRUG NAME	Mepsevii (vestronidase alfa-vjvk)
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Mepsevii is an enzyme replacement therapy (ERT) that was approved by the FDA in 2017 for the treatment of Sly Syndrome, also known as mucopolysaccharidosis type VII (MPS VII).

